TP53 and myelodysplastic syndrome: A Phase Ib/II Eprenetapopt combined with AZA for the treatment of MDS and AML patients with TP53 mutations clinical trial (NCT03072043) found that among 40 MDS patients, ORR was 73%, and CRR reached 50%; at the same time, the patients’ TP53 variant allele frequency (VAF) and p53 protein expression were significantly reduced, and 38% of the patients achieved complete molecular remission (VAF < 5%), laying a solid foundation for subsequent phase III clinical trials, which is expected to change the current treatment landscape (78).